Skip to contentClarengateINTELLIGENCE
Coverage & freshness About Clarengate
Companies/13606487

Neovac Ltd

Research and experimental development on biotechnology · Abingdon

ActiveUnited KingdomIncorporated 2021Private Limited Company
Register Ask analyst

Documents & history

Available account evidence and business events. This is not a complete filing history or document library.

Accounts to 2025-12-31

IXBRL · 134 source facts · 20 selected values

Validation findings
XBRL valid
Reporting period
2025-01-01 to 2025-12-31
Extraction status
complete
Numeric facts
81
Documents processed
1
XBRL standards validation
valid
Filing-profile validation
invalid
Parser
arelle 2.44.4
Taxonomy
FRS-102-2025-01-01.xsd
Currency
GBP
Source identifier
Prod223_4315_13606487_20251231
Source archive
Accounts_Bulk_Data-2026-09-25.zip

Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.

Accounts to 2024-12-31

IXBRL · 138 source facts · 20 selected values

Validation findings
XBRL valid
Reporting period
2024-01-01 to 2024-12-31
Extraction status
complete
Numeric facts
86
Documents processed
1
XBRL standards validation
valid
Filing-profile validation
invalid
Parser
arelle 2.44.4
Taxonomy
FRS-102-2023-01-01.xsd
Currency
GBP
Source identifier
Prod224_2506_13606487_20241231
Source archive
Accounts_Monthly_Data-June2025.zip

Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.

Accounts to 2023-12-31

IXBRL · 138 source facts · 20 selected values

Not assessed
legacy record
Reporting period
2023-10-01 to 2023-12-31
Extraction status
Legacy / not assessed
Numeric facts
87
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2023-01-01.xsd
Currency
GBP
Source identifier
Prod224_3100_13606487_20231231
Source archive
Accounts_Monthly_Data-November2024.zip

Accounts to 2023-09-30

IXBRL · 150 source facts · 20 selected values

Not assessed
legacy record
Reporting period
2022-10-01 to 2023-09-30
Extraction status
Legacy / not assessed
Numeric facts
88
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2023-01-01.xsd
Currency
GBP
Source identifier
Prod224_6666_13606487_20230930
Source archive
Accounts_Monthly_Data-December2023.zip

Accounts to 2022-09-30

IXBRL · 108 source facts · 11 selected values

Not assessed
legacy record
Reporting period
2021-09-07 to 2022-09-30
Extraction status
Legacy / not assessed
Numeric facts
44
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2021-01-01.xsd
Currency
GBP
Source identifier
Prod224_0009_13606487_20220930
Source archive
Accounts_Monthly_Data-March2023.zip

Registered details

13606487
Status
Active
Type
Private Limited Company
Incorporated
2021-09-07
Jurisdiction
—
Registered office
SUITES 1 AND 2, 127 OLYMPIC AVENUE, ABINGDON, OX14 4SA, ENGLAND

Classification

1 SIC codes
72110

Capital & company events

Reconstructed equity rounds and matched research funding.

Equity fundraising

0 SH01-derived rounds

No reconstructed allotment rounds.

Research and innovation

5 matched grants
Glycan-functionalized lipid nanoparticles for targeted mRNA deliveryLeadLive
Innovate UK · Collaborative R&D · 2025-04-01 – 2027-03-31
£599,285
awarded
An mRNA vaccine for Plague: design to clinical efficacy testingLead
Innovate UK · Small Business Research Initiative · 2023-10-01 – 2025-12-31
£1,986,118
awarded
UltiMalVaxLeadLive
Innovate UK · EU-Funded · 2023-05-01 – 2027-04-30
£579,603
awarded
UltiMalVaxLeadActive
Horizon Europe Guarantee · EU-Funded · 2023-04-30 – 2027-04-29
£579,603
whole project
UltiMalVaxActive
Horizon Europe Guarantee · EU-Funded · 2023-04-30 – 2027-04-29
£579,603
whole project